International Clinical Trial: A real-world clinical study of Pralsetinib in the treatment of RET fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) with prophylactic use of leukocyte-increasing drug Leucogen

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120202) titled 'A real-world clinical study of Pralsetinib in the treatment of RET fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) with prophylactic use of leukocyte-increasing drug Leucogen' on March 10.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Fudan University Shanghai Cancer Center

Condition: RET fusion-positive locally advanced or metastatic non-small cell lung cancer(NSCLC)

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-03-10

Target Sample Size: Experimental group:25;

Countries of Recruitment: China

To know more, ...